Meta-Analysis and Systematic Review of Coagulation Disbalances in COVID-19: 41 Studies and 17,601 Patients

Polina Len1, Gaukhar Iskakova1, Zarina Sautbayeva1

  • 1School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan.

Insights

Elevated coagulation markers like D-dimers and fibrinogen are linked to severe COVID-19. Platelet counts were lower in severe cases, suggesting hemostatic changes impact disease severity.

Area of Science:

  • Medical Research
  • Hematology
  • Infectious Diseases

Background:

  • Coagulation parameters are crucial in understanding COVID-19 infection.
  • Early identification of hemostatic alterations can inform disease severity assessment.

Purpose of the Study:

  • To conduct a meta-analysis assessing the association between early hemostatic parameters and COVID-19 infection severity.
  • To identify key coagulation markers indicative of severe SARS-CoV-2 infection.

Main Methods:

  • A systematic electronic search identified studies on COVID-19 patient characteristics and disease severity.
  • Meta-analysis estimated standardized mean differences (SMD) for D-dimers, fibrinogen, prothrombin time, platelet count (PLT), and activated partial thromboplastin time.
  • Sensitivity, subgroup, and publication bias analyses were performed to ensure robustness.

Main Results:

  • Meta-analysis of 41 studies (17,601 patients) revealed significantly higher D-dimers, fibrinogen, activated partial thromboplastin time, and prothrombin time in severe COVID-19 cases.
  • Platelet count (PLT) was significantly lower in patients with severe COVID-19.
  • D-dimers and fibrinogen showed the strongest association with disease severity; publication bias was noted for these markers.

Conclusions:

  • Hemostatic parameters, excluding platelets, are significantly elevated in severe COVID-19.
  • D-dimers and fibrinogen levels are strongly associated with COVID-19 severity.
  • Future research should explore clotting formation and platelet characteristics beyond conventional coagulation tests.
Abstract

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
957
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
50
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
40
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K